Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
HYPD
$2.99
$
A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.
Next Earnings
2026-02-25
Beta
2.707
Average Volume
Market Cap
Last Dividend
CIK
0001682639
ISIN
US30234E2037
CUSIP
30234E104
CEO
Hyunsu Jung
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
13
IPO Date
2025-07-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Average Rating of “Hold” from Analysts | Hyperion DeFi, Inc. (NASDAQ: HYPD - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on | Defense World | 2026-02-19 03:29:06 |
| Hyperion DeFi (NASDAQ:HYPD) CFO David Knox Acquires 27,950 Shares of Stock | Hyperion DeFi, Inc. (NASDAQ: HYPD - Get Free Report) CFO David Knox acquired 27,950 shares of the company's stock in a transaction that occurred on Wednesday, December 31st. The shares were bought at an average price of $3.59 per share, with a total value of $100,340.50. Following the transaction, the chief financial officer owned 327,950 shares | Defense World | 2026-01-06 05:24:59 |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|